US Patent Issued to Bavarian Nordic on Aug. 19 for "Therapy for treating cancer with an intratumoral or intravenous administration of a recombinant MVA encoding 4-1BBL (CD137L) and/or CD40L" (German Inventors)

ALEXANDRIA, Va., Aug. 20 -- United States Patent no. 12,390,515, issued on Aug. 19, was assigned to Bavarian Nordic A/S (Hellerup, Denmark).

"Therapy for treating cancer with an intratumoral or intravenous administration of a recombinant MVA encoding 4-1BBL (CD137L) and/or CD40L" was invented by Henning Lauterbach (Eching, Germany), Maria Hinterberger (Sauerlach, Germany) and Jose Medina Echeverz (Munich).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention relates to a composition and related methods for reducing tumor volume and/or increasing the survival of a cancer patient. The composition comprises a recombinant MVA encoding a Tumor Associated Antigen ("TAA") as well as 4-1BBL and/or CD40L and ca...